Teriparatide biosimilar - USVAlternative Names: Recombinant parathyroid hormone biosimilar - USV
Latest Information Update: 23 May 2015
At a glance
- Originator USV
- Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Registered Osteoporosis
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 09 May 2015 USV files a patent for teriparatide biosimilar before May 2015 (USV product pipeline, May 2015)